Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Specimen Handling 3Biopsy 3sodium-iodide symporter 2fludarabine 2cemiplimab 2X-Rays 2Whole-Body Irradiation 2Stem Cell Transplantation 2Photons 2Nivolumab 2Mycophenolic Acid 2Immunoglobulin G 2Disulfides 2Cyclosporine 2treosulfan 1ruxolitinib 1pembrolizumab 1fludarabine phosphate 1entrectinib 1duvelisib 1alectinib 1Vinblastine 1Tacrolimus 1Standard of Care 1Sirolimus 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × duvelisib × 30 days × Clear all
NCT07001384 2026-05-26

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
30 enrolled
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡